12/16
07:36 am
trvi
Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering
Medium
Report
Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering
12/13
07:32 am
trvi
Trevi's chronic cough trial in IPF subjects continues without sample size change [Yahoo! Finance]
High
Report
Trevi's chronic cough trial in IPF subjects continues without sample size change [Yahoo! Finance]
12/12
01:07 pm
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its price target raised by analysts at HC Wainwright from $6.00 to $7.50. They now have a "buy" rating on the stock.
High
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its price target raised by analysts at HC Wainwright from $6.00 to $7.50. They now have a "buy" rating on the stock.
12/12
12:37 pm
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
High
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
12/12
12:37 pm
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $21.00 price target on the stock.
High
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $21.00 price target on the stock.
12/12
09:48 am
trvi
Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday? [Yahoo! Finance]
High
Report
Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday? [Yahoo! Finance]
12/12
07:36 am
trvi
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough [Yahoo! Finance]
Low
Report
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough [Yahoo! Finance]
12/12
07:30 am
trvi
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
High
Report
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
12/4
12:56 pm
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at HC Wainwright.
Low
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at HC Wainwright.
12/4
08:09 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Low
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
12/4
08:09 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $21.00 price target on the stock.
Low
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $21.00 price target on the stock.
12/3
04:15 pm
trvi
Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine [Yahoo! Finance]
High
Report
Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine [Yahoo! Finance]
12/3
04:05 pm
trvi
Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine
High
Report
Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine
11/21
07:39 am
trvi
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference [Yahoo! Finance]
Low
Report
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference [Yahoo! Finance]
11/21
07:30 am
trvi
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
Low
Report
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
11/8
08:46 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Low
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
11/7
02:31 am
trvi
Trevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: Navigating Increased Losses and ... [Yahoo! Finance]
Medium
Report
Trevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: Navigating Increased Losses and ... [Yahoo! Finance]
11/6
04:05 pm
trvi
Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
Medium
Report
Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
10/30
04:05 pm
trvi
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024
Medium
Report
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024
10/22
08:32 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
10/21
07:30 am
trvi
Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough
Medium
Report
Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough
10/15
07:30 am
trvi
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences
Low
Report
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences
10/7
11:28 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $6.00 price target on the stock.
Low
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $6.00 price target on the stock.
10/4
01:35 pm
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
Neutral
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $8.00 price target on the stock.
10/3
04:05 pm
trvi
Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program
Neutral
Report
Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program